يحاول ذهب - حر
THE Beautiful AND THE Damned
May 09, 2025
|Newsweek Europe
How GLP-1 drugs like MOUNJARO and OZEMPIC are redefining the debate about size, weight loss and PRIVILEGE
SAMHITA MUKHOPADHYAY WASN'T expecting shame to come from a photo. The longtime feminist writer and former Teen Vogue editor had just moderated a panel at a media conference. She was dressed in a skirt and printed top she felt good in—until she saw a candid image someone had posted online. “It was devastating,” she told Newsweek. Mukhopadhyay took Mounjaro, an antidiabetic medication also used for weight loss, and saw dramatic results—losing 15 percent of her body weight over 18 months. She was feeling physically better, sleeping more soundly and even considering a wardrobe overhaul. But the cost of the drug forced her to stop. “I knew better,” she said. “As a feminist writer and committed proponent of body positivity, I'd spent years trying to love my body at any size. And yet, here I was, agonizing over a picture of myself.
That contradiction, she said, was the real heartbreak—not just for her, but for the women who long-embraced the body positivity messaging themselves. “Taking something for weight loss made me feel like I was being vain, that I didn’t have the willpower to lose weight, eat better or exercise,” she said. “It felt like a violation of an unspoken norm.”
Hollywood's Open Secret
IN RECENT YEARS, MOUNJARO AND SIMILAR GLP-1 DRUGS like Wegovy, Ozempic and Zepbound have redefined how America thinks—and talks—about weight. What began as a diabetes treatment has become a billion-dollar industry fueled by off-label use, celebrity whispers and red-carpet transformations.
As the 2025 Hollywood awards season kicked off with the Golden Globes in January, so too did another round of jokes, speculation and sponsorships linking the industry to the use of GLP-1 medications for weight loss by A-list celebrities. Comedian Nikki Glaser, host of the Globes, dove right in at the start of her opening monologue: “Good evening, and welcome to the 82nd Golden Globes—Ozempic’s biggest night,” she began.
هذه القصة من طبعة May 09, 2025 من Newsweek Europe.
اشترك في Magzter GOLD للوصول إلى آلاف القصص المتميزة المنسقة، وأكثر من 9000 مجلة وصحيفة.
هل أنت مشترك بالفعل؟ تسجيل الدخول
المزيد من القصص من Newsweek Europe
Newsweek Europe
THE BENEFITS OF A GUIDING HAND
Well-designed Al governance does not suppress innovation—it shapes its direction in socially beneficial ways
4 mins
May 08-15, 2026
Newsweek Europe
Maternity Hospitals & Fertility Clinics 2026
Newsweek and Statista highlight the fertility clinics and maternity hospitals combining advanced innovation with compassionate care to support families at every step of building a healthy future
3 mins
May 08-15, 2026
Newsweek Europe
Apple's New CEO May Return to Company's Core
As Apple says goodbye to CEO Tim Cook (below, right, affectionately known as Tim Apple by President Donald Trump), its senior vice president of hardware engineering, John Ternus, is stepping up at a crucial time.
1 min
May 08-15, 2026
Newsweek Europe
'CALIFORNIA IS DESPERATE FOR CHANGE'
Steve Hilton is looking to become the first Republican elected governor in the Golden State since Arnold Schwarzenegger. Can his focus on housing, homelessness and the cost of living guide him to victory in November?
5 mins
May 08-15, 2026
Newsweek Europe
Nike Can't Do It Anymore
\"Runners Welcome.
1 mins
May 08-15, 2026
Newsweek Europe
RICHARD GADD
The actor follows Baby Reindeer with Half Man, an HBO limited series about two repressed “brothers” in Glasgow. “I came up with the two characters, and I couldn't shake them.”
2 mins
May 08-15, 2026
Newsweek Europe
The Human Cost of America's Longest Carrier Deployment
The USS Gerald R. Ford has now spent more than 300 days at sea-the longest deployment of any U.S. aircraft carrier since the Vietnam War-and for the nearly 4,500 sailors on board, many of them under the age of 20, the record comes at a cost.
1 min
May 08-15, 2026
Newsweek Europe
WASHINGTON'S #METOO MOMENT
How three Republican lawmakers are leading the drive for sexual conduct accountability in the House
4 mins
May 08-15, 2026
Newsweek Europe
Live Nation Lost. But Who Won?
At the height of Pearl Jam's success in 1994—and nearly eight months after the rock band filed an antitrust complaint against Ticketmaster—Rolling Stone asked, “If Pearl Jam couldn't do it, who can?”
1 min
May 08-15, 2026
Newsweek Europe
Are Foreign Operatives Killing Scientists in the US?
President Donald Trump is hoping it's a \"coincidence.\"
1 min
May 08-15, 2026
Listen
Translate
Change font size
